PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Migrants held for ransom in Texas hoped Biden would welcome them

Show Me

New videos show suspects in ‘most violent attacks’ on cops during Capitol riots

Show Me

Coronavirus Reinfections Are Rare, Danish Researchers Report

Show Me

US Jobless Claims Rise to 770,000 With Layoffs Still High

Show Me

Chilling video shows Atlanta gunman watching his victims enter the spa before killing four

Show Me

Biden nominee Gupta to sell stake in company linked to chemical used by drug cartels in heroin

Show Me

California Recall Backers Submitted 2.1 Million Signatures Ahead Of Deadline – Far Above Required Amount

Show Me

Facebook is making a bracelet that lets you control computers with your brain

Show Me

Teacher vaccinations will likely not be mandatory to reopen schools: education sec

Show Me

March 18, 2021 | Nightly News Rebroadcast | Video: 51 Minutes 53 Seconds

Show Me

Atlanta Shooting Suspect Tells Police Attack Not Racially Motivated

Show Me

Atlanta-area parlor shootings suspect may have ‘sexual addiction,’ police say

Show Me

Suspect In Georgia Shooting Might Have Been A Sex Addict, Police Say

Show Me

Atlanta Shooting May NOT Be Hate Crime, Shooter Claims Sex Addiction: Police

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded March 17, 2021 | 75 Million vs. 435 … The Deplorables Have Power to Save America | Video: 48 Minutes 37 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded March 17, 2021 | Let’s Roll … Open the Schools, not the Border | Video: 48 Minutes 31 Seconds

Show Me

“Hell on Earth”: Yemeni Children Starve to Death as U.S.-Backed Saudi Blockade Devastates Nation

Show Me

Reports of Deaths After COVID Vaccines Up by 259 in 1 Week, CDC Data Show

Show Me

Hundreds of COVID-19 Vaccines Discarded Due to Storage Error at Kansas Hospital

Show Me

Bill Gates: Vaccines Are ‘Phenomenal’ Profit Makers

Show Me

Latest shots-in-arms tally below average — as share of Illinois residents fully vaccinated against COVID-19 hits 12%

Show Me

Updates on CCP Virus: Moderna Begins Study of Vaccine in Kids ( Babies As Young As 6 Months )

Show Me

Country Star Larry Gatlin Tests Positive for COVID-19 After Getting 2nd Moderna Vaccine Dose

Show Me

‘Hypocrisy’ And ‘Lies’: Tara Reade Slams Biden For Praising Courage Of #METOO Accusers

Show Me

Top U.S. officials strike a critical tone toward China during a visit to Japan.

Show Me

Cuomo helped draft letter disparaging his first sexual harassment accuser: report

Show Me

Liberal Circuit Court Judge Charged With Possession Of Child Pornography

Show Me

Convicted Democratic fund-raiser had secret ties to U.S. intelligence

Show Me

Texas Ensures Forgiveness of $29 Mil­lion in Unpaid Elec­tric Bills After Griddy Files for Bankruptcy

Show Me

8 Dead After Shootings at 3 Massage Parlors in Georgia, Man Captured

Show Me

Elderly Asian man dies following California robbery, as hate crimes swell

Show Me

US and Asian Allies Launch Partnership to Supply Billions of Vaccines in Indo-Pacific

Show Me

‘Asian Graduation,’ ‘Black Graduation’: Columbia University Holding 7 Different Ceremonies For Students

Show Me

House panel to hold hearing on violence against Asian Americans

Show Me

Trump on Border Crisis: ‘They’re Going to Destroy Our Country’

Show Me

Biotech researcher bought 800 castor beans to extract ricin, feds say

Show Me

March 16, 2021 | Nightly News Rebroadcast | Video: 52 Minutes 57 Seconds

Show Me

And These Are Supposed To Be The “Real” News Outlets: Washington Post Adds Lengthy Correction To Report On Trump Call With Georgia Elections Investigator

Show Me

ISIS jihadis are ‘beheading CHILDREN as young as 11 in barbaric uprising that’s left 2,500 dead in Mozambique’

Show Me

Facebook Global Planning Lead Reveals Need for Government Intervention: ‘The Single Biggest Thing is this Company Needs to be Broken Up’…‘No King in the History of the World has been the Ruler of Two Billion People, but Mark Zuckerberg is’

Show Me